Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria

doi:10.12998/wjcc.v10.i29.10413

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 29

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3988)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

368

WORD

HTML

2420

Tables (1-3)

227

Sum=3060

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

218

Download

710

Sum=928

Oct 16, 2022 (publication date) through Jul 6, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Cases. Oct 16, 2022; 10(29): 10413-10427
Published online Oct 16, 2022. doi: 10.12998/wjcc.v10.i29.10413

Table 1 Features of liver transplant criteria for hepatocellular carcinoma and survival rates

Criteria	Single Tm LTD in cm	Multiple Tm as NN	Multiple Tm LTD in cm	TTD in cm	AFP in ng/mL	PIVKA II	Differ.	MiVi	LTD + NN	TTV in cm³	GGT in IU/L	5-yr DFS criteria in, %	5-yr OS criteria, %	5-yr recurrence criteria, %
Paul-Brousse	3	1-2	3	-	-	-	-	-	-	-	-	83	83	-
Milan	≤ 5	2-3	≤ 3	-	-	-	-	-	-	-	-	82 (4 yr)	85 (4 yr)	8
UCSF	≤ 6.5	2-3	≤ 4.5	≤ 8	-	-	-	-	-	-	-	-	75.2
BCLC	≤ 7	2-34-5	≤ 5≤ 7	-	-	-	-	-	-	-	-	-	80.2	23.8
Extended criteria	≤ 7.5	2-3	≤ 5	-	-	-	(> 5 cm with poor diff also excluded)	-	-	-		76.8 (4 yr)	82.9 (4 yr)	-
Berlin	≤ 6	No limit	≤ 6	≤ 15	-	-	-	-	-	-	-	64 (3 yr)	68 (3 yr)	-
Kyoto	≤ 5	2-10	≤ 5	-	-	≤ 400	-	-	-	-	-	-	86.7	4.9
Tokyo	≤ 5	2-5	≤ 5	-	-	-	-	-	-	-	-	94 (3 yr)	75	-
Onaca	≤ 6	2-4	≤ 5	-	-	-	-	-	-	-	-	64.6	-	-
Hangzhou	≤ 8	-	-	≤ 8	-	-	-	-	-	-	-	70.7	62.4	-
Hangzhou	> 8	-	-	> 8	≤ 400	-	Well/Moder	-	-	-	-	70.7	62.4	-
Asan	≤ 5	2-6	≤ 5	-	-	-	-	-	-	-	-	-	76.3	13.6 (3 yr)
CUN	≤ 6	2-3	≤ 5	-	-	-	-	-	-	-	-	-	73	-
Valencia	≤ 5	2-3	≤ 5	≤ 10	-	-	-	-	-	-	-	-	67	9
Shangai	≤ 9	2-3	≤ 5	≤ 9	-	-	-	-	-	-	-	52.6	78.1	10.7
Kyushu	≤ 5	No limit	≤ 5	-	-	≤ 300	-	-	-	-	-	87	82.7	-
UpToSeven	≤ 6	-	-	-	-	-	-	Neg.	≤ 7	-	-	-	71.2	39.9
TTV/AFP²⁸	-	-	-	-	≤ 400	-	-	-	-	≤ 115	-	-	Approximately 60 (4 yr)	-
Ext Toronto	No limit	No limit	No limit	-	-	-	Well/Moder	-	-	-	-	-	68	25.6
AFP-TTD	≤ 8	-	-	≤ 8	≤ 400	-	-	-	-	-	-	74.4	-	4.9
Samsung	≤ 6	2-7	≤ 6	-	≤ 1000	-	-	-	-	-	-	89.6	-	-
5-5-500	≤ 5	2-5	≤ 5	-	≤ 500	-	-	-	-	-	-	73.2	75.8	7.3
Malatya	≤ 6	No limit	≤ 6	-	≤ 200	-	Well/Moder	-	-	-	≤ 104	-	79.7	-
Exp Malatya	≤ 10	No limit	≤ 10	-	≤ 200	-	-	-	-	-	≤ 104	-	77.6	-

AFP: Alpha fetoprotein; BCLC: Barcelona Clinic Liver Cancer; CUN: Clinica Universitaria de Navarra criteria; DFS: Disease-free survival; Differ: Differentiation; GGT: Gamma glutamyl transferase; LTD: Largest tumor diameter; MiVi: Microvascular invasion; Moder: Moderate; NN: Number of nodules; OS: Overall survival; PIVKA II: Protein induced vitamin K antagonist II; Tm: Tumor; TTD: Total tumor diameter; TTV: Total tumor volume; UCSF: University of California San Francisco criteria.

Citation: Ince V, Sahin TT, Akbulut S, Yilmaz S. Liver transplantation for hepatocellular carcinoma: Historical evolution of transplantation criteria. World J Clin Cases 2022; 10(29): 10413-10427
URL: https://www.wjgnet.com/2307-8960/full/v10/i29/10413.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i29.10413